<!DOCTYPE html>
<html lang="en" dir="ltr">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <link rel="manifest" href="/manifest.json">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">

  <title>Multiple Myeloma: Information & Treatment | StopMyCancer</title>
  <meta name="description" content="Understanding multiple myeloma. Plasma cell cancer, bone disease, kidney complications, chemotherapy, immunotherapy, stem cell transplant options.">
  <meta name="keywords" content="multiple myeloma, plasma cell cancer, monoclonal antibodies, proteasome inhibitors, immunotherapy, stem cell transplant, lenalidomide, bortezomib">
  <meta name="author" content="StopMyCancer">
  <link rel="canonical" href="https://stopmycancer.com/cancers/myeloma/">

  <meta property="og:type" content="article">
  <meta property="og:title" content="Multiple Myeloma: Information & Treatment">
  <meta property="og:description" content="Comprehensive guide to multiple myeloma, treatment options, and management strategies.">
  <meta property="og:url" content="https://stopmycancer.com/cancers/myeloma/">
  <meta property="og:site_name" content="StopMyCancer">
  <meta property="og:locale" content="en_US">

  <link rel="preconnect" href="https://fonts.googleapis.com">
  <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
  <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700;800&display=swap" rel="stylesheet">
  <link rel="stylesheet" href="/css/styles.css">
  <link rel="icon" type="image/svg+xml" href="data:image/svg+xml,<svg xmlns='http://www.w3.org/2000/svg' viewBox='0 0 100 100'><text y='.9em' font-size='90'>üõ°Ô∏è</text></svg>">
</head>
<body>

  <a href="#main" class="skip-link">Skip to main content</a>

  <header class="header" role="banner">
    <div class="header__inner">
      <a href="/" class="header__logo" aria-label="StopMyCancer Home">
        <div class="header__logo-icon" aria-hidden="true">S</div>
        Stop<span>My</span>Cancer
      </a>

      <nav class="header__nav" role="navigation" aria-label="Main navigation">
        <a href="/cancers/" class="header__nav-link">Cancer Types</a>
        <a href="/navigate/" class="header__nav-link">Navigate</a>
        <a href="/stories/" class="header__nav-link">Stories</a>
        <a href="/access/" class="header__nav-link">Access &amp; Equity</a>
        <a href="/tools/pathology-translator" class="header__nav-link">Translator Tool</a>
        <a href="/about/" class="header__nav-link">About</a>
      </nav>

      <div class="header__actions">
        <div class="lang-switcher">
          <button class="lang-switcher__btn" aria-haspopup="true" aria-expanded="false" aria-label="Change language">
            <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><circle cx="12" cy="12" r="10"></circle><line x1="2" y1="12" x2="22" y2="12"></line><path d="M12 2a15.3 15.3 0 0 1 4 10 15.3 15.3 0 0 1-4 10 15.3 15.3 0 0 1-4-10 15.3 15.3 0 0 1 4-10z"></path></svg>
            EN
            <svg width="12" height="12" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><path d="M6 9l6 6 6-6"></path></svg>
          </button>
          <div class="lang-switcher__dropdown" role="menu">
            <a href="/cancers/myeloma/" class="lang-switcher__option lang-switcher__option--active" role="menuitem">English</a>
          </div>
        </div>

        <button class="mobile-toggle" aria-label="Open menu" aria-expanded="false" aria-controls="mobile-nav">
          <span class="mobile-toggle__line"></span>
          <span class="mobile-toggle__line"></span>
          <span class="mobile-toggle__line"></span>
        </button>
      </div>
    </div>
  </header>

  <nav class="mobile-nav" id="mobile-nav" role="navigation" aria-label="Mobile navigation">
    <a href="/cancers/" class="mobile-nav__link">Cancer Types</a>
    <a href="/navigate/" class="mobile-nav__link">Navigate</a>
    <a href="/stories/" class="mobile-nav__link">Stories</a>
    <a href="/access/" class="mobile-nav__link">Access &amp; Equity</a>
    <a href="/tools/pathology-translator" class="mobile-nav__link">Pathology Translator</a>
    <a href="/about/" class="mobile-nav__link">About</a>
  </nav>

  <main id="main">

    <section class="page-header">
      <div class="container">
        <div class="breadcrumbs" role="navigation" aria-label="Breadcrumbs">
          <a href="/">Home</a> <span aria-hidden="true">/</span> <a href="/cancers/">Cancer Types</a> <span aria-hidden="true">/</span> <span>Multiple Myeloma</span>
        </div>
        <h1>Multiple Myeloma</h1>
        <p class="page-header__subtitle">Understanding plasma cell cancer. Symptoms, complications, and modern treatment approaches including immunotherapy.</p>
      </div>
    </section>

    <section class="main-content">
      <div class="container">
        <div class="grid grid--content-sidebar">

          <article class="article">

            <section class="summary">
              <p><strong>Multiple myeloma is a cancer of plasma cells in the bone marrow.</strong> Plasma cells produce antibodies (immunoglobulins). When myeloma develops, abnormal plasma cells multiply and produce abnormal antibodies, damaging bones and affecting kidney function. Modern treatments have dramatically improved outcomes and quality of life.</p>
            </section>

            <section>
              <h2>What Is Multiple Myeloma?</h2>
              <p>Multiple myeloma originates in the bone marrow. Cancerous plasma cells accumulate, crowding out healthy cells and producing excess abnormal immunoglobulin (M-protein). This causes bone destruction, anemia, kidney damage, and infections.</p>
              <p><strong>Key fact:</strong> Myeloma can be preceded by precursor conditions (MGUS, smoldering myeloma) and monitored with blood tests (M-protein levels, free light chains) before active disease requires treatment.</p>
            </section>

            <section>
              <h2>Risk Factors</h2>
              <ul>
                <li><strong>Age:</strong> Median age at diagnosis is 70 years old.</li>
                <li><strong>Male sex:</strong> Men have higher incidence than women.</li>
                <li><strong>Race/ethnicity:</strong> African Americans have 2x higher incidence and often worse outcomes.</li>
                <li><strong>Family history:</strong> Familial clustering increases risk.</li>
                <li><strong>Obesity and occupational exposures:</strong> Possible risk factors under investigation.</li>
              </ul>
            </section>

            <section>
              <h2>Symptoms &amp; Complications</h2>
              <p><strong>CRAB criteria</strong> define symptomatic myeloma:</p>
              <ul>
                <li><strong>C:</strong> Calcium elevation (bone disease)</li>
                <li><strong>R:</strong> Renal insufficiency (kidney damage)</li>
                <li><strong>A:</strong> Anemia (low hemoglobin)</li>
                <li><strong>B:</strong> Bone lesions (on imaging)</li>
              </ul>
              <p><strong>Other symptoms:</strong></p>
              <ul>
                <li>Bone pain (especially back, ribs)</li>
                <li>Fractures (weakened bones)</li>
                <li>Fatigue and weakness</li>
                <li>Recurrent infections</li>
                <li>Kidney dysfunction</li>
                <li>Hyperviscosity (thick blood causing confusion, bleeding)</li>
              </ul>
            </section>

            <section>
              <h2>Diagnosis</h2>
              <p><strong>Diagnostic workup:</strong></p>
              <ul>
                <li><strong>Blood tests:</strong> CBC (hemoglobin, platelets), chemistry panel (calcium, creatinine), LDH, albumin, beta-2 microglobulin.</li>
                <li><strong>M-protein detection:</strong> Serum protein electrophoresis, immunofixation, quantitative immunoglobulin levels.</li>
                <li><strong>Free light chains:</strong> Prognostic marker; high ratio predicts aggressive disease.</li>
                <li><strong>Bone marrow biopsy:</strong> Confirms clonal plasma cells (‚â•10% diagnostic).</li>
                <li><strong>Imaging:</strong> Skeletal survey, MRI, or PET scan to assess bone disease.</li>
                <li><strong>Molecular testing:</strong> Cytogenetic abnormalities (t(4;14), del17p) and FISH studies guide risk stratification.</li>
              </ul>
            </section>

            <section>
              <h2>Staging &amp; Risk Stratification</h2>
              <p>Revised International Staging System (R-ISS) incorporates:</p>
              <ul>
                <li>Serum beta-2 microglobulin</li>
                <li>Albumin level</li>
                <li>Cytogenetic abnormalities</li>
              </ul>
              <p>Risk categories guide treatment intensity and prognosis.</p>
            </section>

            <section>
              <h2>Treatment Options</h2>

              <h3>Watch-and-Wait (Smoldering/MGUS)</h3>
              <p>For precursor states or early asymptomatic disease, close monitoring with blood/imaging without immediate treatment.</p>

              <h3>Proteasome Inhibitors</h3>
              <p>Bortezomib (Velcade), carfilzomib (Kyprolis), ixazomib (Ninlaro). Reversibly inhibit proteasome degradation of proteins, triggering cancer cell death. Often first-line.</p>

              <h3>Immunomodulatory Agents (IMiDs)</h3>
              <p>Lenalidomide (Revlimid), pomalidomide (Pomalyst). Enhance immune killing of myeloma cells and have anti-angiogenic effects.</p>

              <h3>Monoclonal Antibodies</h3>
              <p>Daratumumab (Darzalex), elotuzumab (Empliciti). Target myeloma cell surface antigens (CD38, SLAMF7) and enhance immune recognition.</p>

              <h3>Stem Cell Transplantation (SCT)</h3>
              <p>High-dose chemotherapy followed by reinfusion of patient's own stem cells. Often used in younger/fit patients as consolidation after induction therapy. Improves complete response rates and progression-free survival.</p>

              <h3>CAR-T Cell Therapy</h3>
              <p>Emerging option for relapsed/refractory myeloma. Idecabtagene vicleucel (Abecma) is FDA-approved. Engineered T cells attack myeloma cells expressing BCMA.</p>

              <h3>Bi-specific Antibodies</h3>
              <p>Newer agents that bridge myeloma cells to immune cells for destruction.</p>
            </section>

            <section>
              <h2>Side Effects &amp; Management</h2>
              <p><strong>From proteasome inhibitors:</strong> Peripheral neuropathy (nerve damage), diarrhea, fatigue, low blood counts.</p>
              <p><strong>From IMiDs:</strong> Blood clots (require anticoagulation), low blood counts, fatigue, neuropathy.</p>
              <p><strong>From monoclonal antibodies:</strong> Infusion reactions, infections (enhanced immunotherapy can be a double-edged sword), tumor flare.</p>
              <p><strong>From SCT:</strong> Severe infections, bleeding, organ toxicity, secondary malignancies (rare).</p>
              <p><strong>Supportive care essential:</strong> Anticoagulation, antimicrobial prophylaxis, bone-directed therapy (bisphosphonates or RANKL inhibitors for bone disease and pain), pain management.</p>
            </section>

            <section>
              <h2>Prognosis &amp; Outcomes</h2>
              <p>Multiple myeloma was incurable, but modern therapies have transformed outcomes:</p>
              <ul>
                <li><strong>Median overall survival:</strong> 5-10 years with current treatments (improvement from 3 years a decade ago).</li>
                <li><strong>Standard-risk:</strong> Often 10+ years with multiagent therapy.</li>
                <li><strong>High-risk:</strong> Shorter median survival but still achievable remissions with aggressive treatment.</li>
              </ul>
              <p><strong>Most patients will eventually relapse,</strong> but newer therapies provide multiple lines of treatment options.</p>
            </section>

            <section class="urgent-box">
              <h2>Seek Immediate Care If You Experience:</h2>
              <ul>
                <li>Severe bone pain uncontrolled by medication</li>
                <li>Signs of spinal cord compression (numbness/weakness in legs)</li>
                <li>Severe kidney dysfunction or oliguria (low urine output)</li>
                <li>Hyperviscosity symptoms (confusion, severe headache, visual changes)</li>
              </ul>
            </section>

            <section>
              <h2>Key Questions for Your Doctor</h2>
              <ul>
                <li>What is my disease stage and risk category?</li>
                <li>Do I need treatment now, or should I watch and wait?</li>
                <li>Am I a candidate for stem cell transplantation?</li>
                <li>What is the planned treatment regimen and expected response?</li>
                <li>What side effects should I monitor for?</li>
                <li>How often will we monitor my M-protein and kidney function?</li>
                <li>Are there new therapies or clinical trials available for my disease?</li>
              </ul>
            </section>

          </article>

        </div>
      </div>
    </section>

  </main>

  <footer class="footer">
    <div class="container">
      <div class="footer__content">
        <div class="footer__section">
          <h3>StopMyCancer</h3>
          <p>Your cancer. Explained. Supported. Navigated.</p>
        </div>
        <div class="footer__section">
          <h4>Navigation</h4>
          <ul>
            <li><a href="/cancers/">Cancer Types</a></li>
            <li><a href="/navigate/">Navigate</a></li>
            <li><a href="/stories/">Stories</a></li>
            <li><a href="/access/">Access &amp; Equity</a></li>
          </ul>
        </div>
        <div class="footer__section">
          <h4>Resources</h4>
          <ul>
            <li><a href="/tools/pathology-translator">Pathology Translator</a></li>
            <li><a href="/about/">About</a></li>
            <li><a href="https://github.com/fantravel1/stopmycancer" target="_blank">GitHub</a></li>
          </ul>
        </div>
      </div>
      <div class="footer__bottom">
        <p>&copy; 2025 StopMyCancer. Licensed under CC BY 4.0.</p>
      </div>
    </div>
  </footer>

  <script src="/js/main.js"></script>

</body>
</html>
